Attenuation of antidepressant effects of ketamine by opioid receptor antagonism

American Journal of Psychiatry

Volumn 175, Issue 12, 2018, Pages 1205-1215

  Williams, Nolan R ^a,b   Heifets, Boris D ^a,b   Blasey, Christine ^a,b   Sudheimer, Keith ^a,b   Pannu, Jaspreet ^a,b   Pankow, Heather ^a,b   Hawkins, Jessica ^a,b   Birnbaum, Justin ^a,b   Lyons, David M ^a,b   Rodriguez, Carolyn I ^a,b   Schatzberg, Alan F ^a,b  

^a STANFORD UNIVERSITY   (United States)

^b PALO ALTO UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

KETAMINE; NALTREXONE; OPIATE RECEPTOR; PLACEBO; ANTIDEPRESSANT AGENT; NARCOTIC ANTAGONIST;

ADULT; ANTIDEPRESSANT ACTIVITY; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; CROSSOVER PROCEDURE; DOUBLE BLIND PROCEDURE; DRUG ANTAGONISM; DRUG RESPONSE; FEMALE; HAMILTON DEPRESSION RATING SCALE; HUMAN; MALE; MENTAL DISSOCIATION; NAUSEA; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; TREATMENT RESISTANT DEPRESSION; VOMITING; DRUG ADMINISTRATION; PSYCHOLOGICAL RATING SCALE;

ADULT; ANTIDEPRESSIVE AGENTS; CROSS-OVER STUDIES; DEPRESSIVE DISORDER, TREATMENT-RESISTANT; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; KETAMINE; MALE; NALTREXONE; NARCOTIC ANTAGONISTS; PSYCHIATRIC STATUS RATING SCALES;

EID: 85055654635     PISSN: 0002953X     EISSN: 15357228     Source Type: Journal    
DOI: 10.1176/appi.ajp.2018.18020138     Document Type: Article

References (119)

1. Friedrich MJ: Depression is the leading cause of disability around the world. JAMA 2017; 317:1517
2. Hyman SE: Revolution stalled. Sci Transl Med 2012; 4:155cm11
3. Rush AJ, Trivedi MH, Wisniewski SR, et al: Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: a STAR*D report. Am J Psychiatry 2006; 163: 1905-1917
4. Williams NR, Taylor JJ, Kerns S, et al: Interventional psychiatry: why now? J Clin Psychiatry 2014; 75:895-897
5. Williams NR, Schatzberg AF: NMDA antagonist treatment of depression. Curr Opin Neurobiol 2016; 36:112-117
6. Autry AE, Adachi M, Nosyreva E, et al: NMDA receptor blockade at rest triggers rapid behavioural antidepressant responses. Nature 2011; 475:91-95
7. Zanos P, Moaddel R, Morris PJ, et al: NMDAR inhibition-independent antidepressant actions of ketamine metabolites. Nature 2016; 533:481-486
8. Niesters M, Martini C, Dahan A: Ketamine for chronic pain: risks and benefits. Br J Clin Pharmacol 2014; 77:357-367
9. Pacheco Dda F, Romero TR, Duarte ID: Central antinociception induced by ketamine is mediated by endogenous opioids and m- and d-opioid receptors. Brain Res 2014; 1562:69-75
10. Schatzberg AF: A word to the wise about ketamine. Am J Psychiatry 2014; 171:262-264
11. Sanacora G, Schatzberg AF: Ketamine: promising path or false prophecy in the development of novel therapeutics for mood disorders? Neuropsychopharmacology 2015; 40:1307
12. Murrough JW, Perez AM, Pillemer S, et al: Rapid and longer-term antidepressant effects of repeated ketamine infusions in treatment-resistant major depression. Biol Psychiatry 2013; 74:250-256
13. White PF, Way WL, Trevor AJ: Ketamine: its pharmacology and therapeutic uses. Anesthesiology 1982; 56:119-136
14. Domino EF, Chodoff P, Corssen G: Pharmacologic effects of Ci-581, a new dissociative anesthetic, in man. Clin Pharmacol Ther 1965; 6:279-291
15. Vollenweider FX, Leenders KL, Oye I, et al: Differential psychopathology and patterns of cerebral glucose utilisation produced by (S)- and (R)-ketamine in healthy volunteers using positron emission tomography (PET). Eur Neuropsychopharmacol 1997; 7: 25-38
16. Vollenweider FX, Vontobel P, Oye I, et al: Effects of (S)-ketamine on striatal dopamine: a [11C]raclopride PET study of a model psychosis in humans. J Psychiatr Res 2000; 34:35-43
17. Dakwar E, Anerella C, Hart CL, et al: Therapeutic infusions of ketamine: do the psychoactive effects matter? Drug Alcohol Depend 2014; 136:153-157
18. Luckenbaugh DA, Niciu MJ, Ionescu DF, et al: Do the dissociative side effects of ketamine mediate its antidepressant effects? J Affect Disord 2014; 159:56-61
19. Krystal JH, D'Souza DC, Petrakis IL, et al: NMDA agonists and antagonists as probes of glutamatergic dysfunction and pharma-cotherapies in neuropsychiatric disorders. Harv Rev Psychiatry 1999; 7:125-143
20. Johnson MW, MacLean KA, Reissig CJ, et al: Human psycho-pharmacology and dose-effects of salvinorin A, a kappa opioid agonist hallucinogen present in the plant Salvia divinorum. Drug Alcohol Depend 2011; 115:150-155
21. Nemeth CL, Paine TA, Rittiner JE, et al: Role of kappa-opioid receptors in the effects of salvinorin A and ketamine on attention in rats. Psychopharmacology (Berl) 2010; 210:263-274
22. Krystal JH, Madonick S, Perry E, et al: Potentiation of low dose ketamine effects by naltrexone: potential implications for the phar-macotherapy of alcoholism. Neuropsychopharmacology 2006; 31: 1793-1800
23. Lee MC, Wagner HN Jr, Tanada S, et al: Duration of occupancy of opiate receptors by naltrexone. J Nucl Med 1988; 29:1207-1211
24. American Psychiatric Association: Diagnostic and Statistical Manual of Mental Disorders, 5th edition: DSM-5. Washington, DC, American Psychiatric Association, 2013
25. Hamilton M: A rating scale for depression. J Neurol Neurosurg Psychiatry 1960; 23:56-62
26. Chandler GM, Iosifescu DV, Pollack MH, et al: RESEARCH: Validation of the Massachusetts General Hospital Antidepressant Treatment History Questionnaire (ATRQ). CNS Neurosci Ther 2010; 16:322-325
27. Newport DJ, Carpenter LL, McDonald WM, et al: Ketamine and other NMDA antagonists: early clinical trials and possible mechanisms in depression. Am J Psychiatry 2015; 172:950-966
28. Bremner JD, Krystal JH, Putnam FW, et al: Measurement of dissociative states with the Clinician-Administered Dissociative States Scale (CADSS). J Trauma Stress 1998; 11:125-136
29. Piantadosi S: Clinical Trials: A Methodologic Perspective. Hoboken, NJ, John Wiley & Sons, 2005
30. Zarate CA Jr, Singh JB, Carlson PJ, et al: A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression. Arch Gen Psychiatry 2006; 63:856-864
31. Frank E, Prien RF, Jarrett RB, et al: Conceptualization and rationale for consensus definitions of terms in major depressive disorder: remission, recovery, relapse, and recurrence. Arch Gen Psychiatry 1991; 48:851-855
32. Jayaram-Lindström N, Guterstam J, Häggkvist J, et al: Naltrexone modulates dopamine release following chronic, but not acute amphetamine administration: a translational study. Transl Psychiatry 2017; 7:e1104
33. Pettinati HM, Oslin DW, Kampman KM, et al: A double-blind, placebo-controlled trial combining sertraline and naltrexone for treating co-occurring depression and alcohol dependence. Am J Psychiatry 2010; 167:668-675
34. Adamson SJ, Sellman JD, Foulds JA, et al: A randomized trial of combined citalopram and naltrexone for nonabstinent outpatients with co-occurring alcohol dependence and major depression. J Clin Psychopharmacol 2015; 35:143-149
35. Malcolm R, O'Neil PM, Von JM, et al: Naltrexone and dysphoria: a double-blind placebo controlled trial. Biol Psychiatry 1987; 22: 710-716
36. Murphy BL, Ravichandran C, Babb SM, et al: Naltrexone in bipolar disorder with depression: a double-blind, placebo-controlled study. J Clin Psychopharmacol 2014; 34:749-751
37. Miotto K, McCann M, Basch J, et al: Naltrexone and dysphoria: fact or myth? Am J Addict 2002; 11:151-160
38. Samuels BA, Nautiyal KM, Kruegel AC, et al: The behavioral effects of the antidepressant tianeptine require the mu-opioid receptor. Neuropsychopharmacology 2017; 42:2052-2063
39. Weber MM, Emrich HM: Current and historical concepts of opiate treatment in psychiatric disorders. Int Clin Psychopharmacol 1988; 3:255-266
40. Lutz PE, Kieffer BL: Opioid receptors: distinct roles in mood disorders. Trends Neurosci 2013; 36:195-206
41. Fava M, Memisoglu A, Thase ME, et al: Opioid modulation with buprenorphine/samidorphan as adjunctive treatment for inadequate response to antidepressants: a randomized double-blind placebo-controlled trial. Am J Psychiatry 2016; 173:499-508
42. Yovell Y, Bar G, Mashiah M, et al: Ultra-low-dose buprenorphine as a time-limited treatment for severe suicidal ideation: a randomized controlled trial. Am J Psychiatry 2016; 173:491-498
43. Bodkin JA, Zornberg GL, Lukas SE, et al: Buprenorphine treatment of refractory depression. J Clin Psychopharmacol 1995; 15:49-57
44. Kalin NH, Shelton SE: Defensive behaviors in infant rhesus monkeys: environmental cues and neurochemical regulation. Science 1989; 243:1718-1721
45. Kalin NH, Shelton SE, Barksdale CM: Opiate modulation of separation-induced distress in non-human primates. Brain Res 1988; 440:285-292
46. Rodriguez CI, Kegeles LS, Levinson A, et al: Randomized controlled crossover trial of ketamine in obsessive-compulsive disorder: proof-of-concept. Neuropsychopharmacology 2013; 38:2475-2483
47. Koran LM, Aboujaoude E, Bullock KD, et al: Double-blind treatment with oral morphine in treatment-resistant obsessive-compulsive disorder. J Clin Psychiatry 2005; 66:353-359
48. Scarone S, Gambini O, Calabrese G, et al: Asymmetrical distribution of beta-endorphin in cerebral hemispheres of suicides: preliminary data. Psychiatry Res 1990; 32:159-166
49. Gross-Isseroff R, Dillon KA, Israeli M, et al: Regionally selective increases in mu opioid receptor density in the brains of suicide victims. Brain Res 1990; 530:312-316
50. Gabilondo AM, Meana JJ, García-Sevilla JA: Increased density of mu-opioid receptors in the postmortem brain of suicide victims. Brain Res 1995; 682:245-250
51. Carlezon WA Jr, Béguin C, Knoll AT, et al: Kappa-opioid ligands in the study and treatment of mood disorders. Pharmacol Ther 2009; 123:334-343
52. Codd EE, Shank RP, Schupsky JJ, et al: Serotonin and norepinephrine uptake inhibiting activity of centrally acting analgesics: structural determinants and role in antinociception. J Pharmacol Exp Ther 1995; 274:1263-1270
53. Zádor F, Király K, Váradi A, et al: New opioid receptor antagonist: naltrexone-14-O-sulfate synthesis and pharmacology. Eur J Pharmacol 2017; 809:111-121
54. Weerts EM, Kim YK, Wand GS, et al: Differences in delta- and mu-opioid receptor blockade measured by positron emission tomography in naltrexone-treated recently abstinent alcohol-dependent subjects. Neuropsychopharmacology 2008; 33:653-665
55. Ebner SR, Roitman MF, Potter DN, et al: Depressive-like effects of the kappa opioid receptor agonist salvinorin A are associated with decreased phasic dopamine release in the nucleus accumbens. Psychopharmacology (Berl) 2010; 210:241-252
56. Taylor GT, Manzella F: Kappa opioids, salvinorin A, and major depressive disorder. Curr Neuropharmacol 2016; 14:165-176
57. Hirota K, Okawa H, Appadu BL, et al: Stereoselective interaction of ketamine with recombinant mu, kappa, and delta opioid receptors expressed in Chinese hamster ovary cells. Anesthesiology 1999; 90: 174-182
58. Yao N, Skiteva O, Zhang X, et al: Ketamine and its metabolite (2R,6R)-hydroxynorketamine induce lasting alterations in glutamatergic synaptic plasticity in the mesolimbic circuit. Mol Psychiatry (Epub ahead of print, Nov 21, 2017)
59. Cavalleri L, Pich EM, Millan M, et al: Ketamine enhances structural plasticity in mouse mesencephalic and human iPSC-derived do-paminergic neurons via AMPAR-driven BDNF and mTOR signaling. Mol Psychiatry 2017; 23:812-823
60. Suzuki K, Nosyreva E, Hunt KW, et al: Effects of a ketamine metabolite on synaptic NMDAR function. Nature 2017; 546:E1-E3
61. Li N, Lee B, Liu R-J, et al: mTOR-dependent synapse formation underlies the rapid antidepressant effects of NMDA antagonists. Science 2010; 329:959-964
62. Monteggia LM, Gideons E, Kavalali ET: The role of eukaryotic elongation factor 2 kinase in rapid antidepressant action of ketamine. Biol Psychiatry 2013; 73:1199-1203
63. Duman RS, Aghajanian GK, Sanacora G, et al: Synaptic plasticity and depression: new insights from stress and rapid-acting antidepressants. Nat Med 2016; 22:238-249
64. Gálvez V, Nikolin S, Ho KA, et al: Increase in PAS-induced neu-roplasticity after a treatment course of intranasal ketamine for depression: report of three cases from a placebo-controlled trial. Compr Psychiatry 2017; 73:31-34
65. Timmerby N, Andersen JH, Søndergaard S, et al: A systematic review of the clinimetric properties of the 6-item version of the Hamilton Depression Rating Scale (HAM-D6). Psychother Psy-chosom 2017; 86:141-149
66. Jonkman K, Dahan A, van de Donk T, et al: Ketamine for pain. F1000 Res 2017; 6(F1000 Faculty Rev):1711 (doi: 10.12688/f1000research. 11372.1)
67. Hustveit O, Maurset A, Oye I: Interaction of the chiral forms of ketamine with opioid, phencyclidine, sigma and muscarinic receptors. Pharmacol Toxicol 1995; 77:355-359
68. Baker AK, Hoffmann VLH, Meert TF: Dextromethorphan and ketamine potentiate the antinociceptive effects of mu- but not delta- or kappa-opioid agonists in a mouse model of acute pain. Pharmacol Biochem Behav 2002; 74:73-86
69. Ryder S, Way WL, Trevor AJ: Comparative pharmacology of the opticalisomersofketamineinmice.EurJPharmacol1978;49:15-23
70. Sarton E, Teppema LJ, Olievier C, et al: The involvement of the mu-opioid receptor in ketamine-induced respiratory depression and antinociception. Anesth Analg 2001; 93:1495-1500
71. Koppert W, Sittl R, Scheuber K, et al: Differential modulation of remifentanil-induced analgesia and postinfusion hyperalgesia by S-ketamineandclonidineinhumans.Anesthesiology2003;99:152-159
72. Sleigh J, Harvey M, Voss L, Denny B. Ketamine: more mechanisms of action than just NMDA blockade. Trends in anaesthesia and critical care. 2014;4(2):76-81.
73. Finck AD, Ngai SH: Opiate receptor mediation of ketamine analgesia. Anesthesiology 1982; 56:291-297
74. Smith DJ, Bouchal RL, deSanctis CA, et al: Properties of the interaction between ketamine and opiate binding sites in vivo and in vitro. Neuropharmacology 1987; 26:1253-1260
75. Sałat K, Siwek A, Starowicz G, et al: Antidepressant-like effects of ketamine, norketamine, and dehydronorketamine in forced swim test: role of activity at NMDA receptor. Neuropharmacology 2015; 99:301-307
76. Commons KG, van Bockstaele EJ, Pfaff DW: Frequent colocali-zation of mu opioid and NMDA-type glutamate receptors at post-synaptic sites in periaqueductal gray neurons. J Comp Neurol 1999; 408:549-559
77. Rodríguez-Muñoz M, Sánchez-Blázquez P, Vicente-Sánchez A, et al: The mu-opioid receptor and the NMDA receptor associate in PAG neurons: implications in pain control. Neuropsychopharmacology 2012; 37:338-349
78. Chartoff EH, Connery HS: It's MORe exciting than mu: crosstalk between mu opioid receptors and glutamatergic transmission in the mesolimbic dopamine system. Front Pharmacol 2014; 5:116
79. Volkow ND, Collins FS: The role of science in addressing the opioid crisis. N Engl J Med 2017; 377:391-394
80. Curtin SC, Warner M, Hedegaard H: Increase in suicide in the United States, 1999-2014. NCHS Data Brief, Apr 2016; 241:1-8
81. Karp JF, Butters MA, Begley AE, et al: Safety, tolerability, and clinical effect of low-dose buprenorphine for treatment-resistant depression in midlife and older adults. J Clin Psychiatry 2014; 75: e785-e793
82. Scherrer JF, Salas J, Sullivan MD, et al: The influence of prescription opioid use duration and dose on development of treatment resistant depression. Prev Med 2016; 91:110-116
83. Leander JD: Buprenorphine is a potent kappa-opioid receptor antagonist in pigeons and mice. Eur J Pharmacol 1988; 151:457-461
84. Leander JD: Buprenorphine has potent kappa opioid receptor antagonist activity. Neuropharmacology 1987; 26:1445-1447
85. Leander JD: Opioid agonist and antagonist behavioural effects of buprenorphine. Br J Pharmacol 1983; 78:607-615
86. Davis MA, Lin LA, Liu H, et al: Prescription opioid use among adults with mental health disorders in the United States. J Am Board Fam Med 2017; 30:407-417
87. Fan N, Xu K, Ning Y, et al: Development of a checklist of short-term and long-term psychological symptoms associated with ketamine use. Shanghai Jingshen Yixue 2015; 27:186-194
88. Kalsi SS, Wood DM, Dargan PI: The epidemiology and patterns of acute and chronic toxicity associated with recreational ketamine use. Emerg Health Threats J 2011; 4:7107
89. Ng SH, Tse ML, Ng HW, et al: Emergency department presentation of ketamine abusers in Hong Kong: a review of 233 cases. Hong Kong Med J 2010; 16:6-11
90. Liao Y, Tang J, Ma M, et al: Frontal white matter abnormalities following chronic ketamine use: a diffusion tensor imaging study. Brain 2010; 133:2115-2122
91. Sassano-Higgins S, Baron D, Juarez G, et al: A review of ketamine abuse and diversion. Depress Anxiety 2016; 33:718-727
92. Fang YX, Wang YB, Shi J, et al: Recent trends in drug abuse in China. Acta Pharmacol Sin 2006; 27:140-144
93. Ahmed SN, Petchkovsky L: Abuse of ketamine. Br J Psychiatry 1980; 137:303
94. Amann LC, Halene TB, Ehrlichman RS, et al: Chronic ketamine impairs fear conditioning and produces long-lasting reductions in auditory evoked potentials. Neurobiol Dis 2009; 35:311-317
95. Morgan CJ, Dodds CM, Furby H, et al: Long-term heavy ketamine use is associated with spatial memory impairment and altered hippocampal activation. Front Psychiatry 2014; 5:149
96. Shiroma PR, Albott CS, Johns B, et al: Neurocognitive performance and serial intravenous subanesthetic ketamine in treatment-resistant depression. Int J Neuropsychopharmacol 2014; 17: 1805-1813
97. Lindefors N, Barati S, O'Connor WT: Differential effects of single and repeated ketamine administration on dopamine, serotonin, and GABA transmission in rat medial prefrontal cortex. Brain Res 1997; 759:205-212
98. Bonnet U: Long-term ketamine self-injections in major depressive disorder: focus on tolerance in ketamine's antidepressant response and the development of ketamine addiction. J Psychoactive Drugs 2015; 47:276-285
99. Prekupec MP Sr, Sher Y, Lembke A: Relapse on ketamine followed by severe and prolonged withdrawal: a cautionary case and review of potential medical therapies. J Nat Sci 2017; 3:e450
100. Byer DE, Gould AB Jr: Development of tolerance to ketamine in an infant undergoing repeated anesthesia. Anesthesiology 1981; 54: 255-256
101. Cumming JF: The development of an acute tolerance to ketamine. Anesth Analg 1976; 55:788-791
102. Stevens RW, Hain WR: Tolerance to rectal ketamine in paediatric anaesthesia. Anaesthesia 1981; 36:1089-1093
103. Błachut M, Sołowiów K, Janus A, et al: [A case of ketamine dependence]. Psychiatr Pol 2009; 43:593-599 (Polish)
104. Critchlow DG: A case of ketamine dependence with discontinuation symptoms. Addiction 2006; 101:1212-1213
105. Florkowski A, Ferfecki L: [A case of ketamine dependence]. Psychiatr Pol 1987; 21:434-435 (Polish)
106. Bobo WV, Miller SC: Ketamine as a preferred substance of abuse. Am J Addict 2002; 11:332-334
107. Lim DK: Ketamine associated psychedelic effects and dependence. Singapore Med J 2003; 44:31-34
108. Pouget P, Wattiez N, Rivaud-Péchoux S, et al: Rapid development of tolerance to sub-anaesthetic dose of ketamine: an oculomotor study in macaque monkeys. Psychopharmacology (Berl) 2010; 209:313-318
109. Livingston A, Waterman AE: The development of tolerance to ketamine in rats and the significance of hepatic metabolism. Br J Pharmacol 1978; 64:63-69
110. Short B, Fong J, Galvez V, et al: Side-effects associated with ketamine use in depression: a systematic review. Lancet Psychiatry 2018; 5:65-78
111. Daly EJ, Singh JB, Fedgchin M, et al: Efficacy and safety of intranasal esketamine adjunctive to oral antidepressant therapy in treatment-resistant depression: a randomized clinical trial. JAMA Psychiatry 2018; 75:139-148
112. Ryan CJ, Loo C: The practicalities and ethics of ketamine for depression. Lancet Psychiatry 2017; 4:354-355
113. Singh I, Morgan C, Curran V, et al: Ketamine treatment for depression: opportunities for clinical innovation and ethical foresight. Lancet Psychiatry 2017; 4:419-426
114. Schak KM, Vande Voort JL, Johnson EK, et al: Potential risks of poorly monitored ketamine use in depression treatment. Am J Psychiatry 2016; 173:215-218
115. Kraemer HC, Blasey C: How Many Subjects? Statistical Power Analysis in Research, 2nd ed. Los Angeles, Sage Publications, 2016
116. Ziauddeen H, Chamberlain SR, Nathan PJ, et al: Effects of the mu-opioid receptor antagonist GSK1521498 on hedonic and con-summatory eating behaviour: a proof of mechanism study in binge-eating obese subjects. Mol Psychiatry 2013; 18:1287-1293
117. 11 C]ABP688 and PET imaging study in depression. Mol Psychiatry 2018; 23:824-832
118. Albert PR, Benkelfat C: The neurobiology of depression: revisiting the serotonin hypothesis, II: genetic, epigenetic, and clinical studies. Philos Trans R Soc Lond B Biol Sci 2013; 368:20120535
119. Albert PR, Benkelfat C, Descarries L: The neurobiology of depression: revisiting the serotonin hypothesis, I: cellular and molecular mechanisms. Philos Trans R Soc Lond B Biol Sci 2012; 367:2378-2381